Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup – the “ATRESS” phenomenon

Patriek Jurrius, Thomas Green, Hans Garmo, Matthew Young, Massimiliano Cariati, Cheryl Gillett, Anca Mera, Mark Harries, Anita Grigoriadis, Sarah Pinder, Lars Holmberg, Arnie Purushotham*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)


Background: Major advances in breast cancer treatment have led to a reducuction in mortality. However, there are still women who are not cured. We hypothesize there is a sub-group of women with treatment-resistant cancers causing early death. Methods: Between 1975 and 2006, 5392 women with invasive breast cancer underwent surgery at Guy's Hospital, London. Data on patient demographics, tumour characteristics, treatment regimens, local recurrence, secondary metastasis, and death were prospectively recorded. We considered four time periods (1975–1982, 1983–1990, 1991–1998, 1999–2006). Risks and time to event analysis were performed with Cox proportional hazards model and Kaplan-Meier estimation. Results: Unadjusted hazard ratios for developing metastasis and overall mortality relative to the 1975–1982 cohort decreased steadily to 0.23 and 0.63, respectively in 1999–2006. However, metastasis-free interval shortened, with the proportion of women developing metastasis ≤5 years increasing from 73.9% to 83.0%. Furthermore, median post-metastatic survival decreased from 1.49 years to 0.94 years. Applying our risk criteria identified the presence of ±200 patients in each cohort who developed metastasis early and died within a much shorter time frame. Conclusions: Advances in treatment have decreased the risk of metastasis and improved survival in women with invasive breast cancer over the last 40 years. Despite this, a subpopulation with shorter metastasis-free and post-metastatic survival who are unresponsive to available treatment remains. This may be due to the ATRESS phenomenon (adjuvant therapy-related shortening of survival) secondary to preselection inherent in adjuvant therapy, successful treatment of less malignant tumour cells and treatment-induced resistance in the remaining tumour clones.

Original languageEnglish
Pages (from-to)39-48
Number of pages10
Publication statusPublished - 1 Apr 2020


  • Breast cancer
  • Post-metastatic survival
  • Prognosis
  • Treatment resistance


Dive into the research topics of 'Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup – the “ATRESS” phenomenon'. Together they form a unique fingerprint.

Cite this